Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18164265rdf:typepubmed:Citationlld:pubmed
pubmed-article:18164265lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:18164265lifeskim:mentionsumls-concept:C0205402lld:lifeskim
pubmed-article:18164265lifeskim:mentionsumls-concept:C0016897lld:lifeskim
pubmed-article:18164265lifeskim:mentionsumls-concept:C0442805lld:lifeskim
pubmed-article:18164265lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:18164265lifeskim:mentionsumls-concept:C2697371lld:lifeskim
pubmed-article:18164265lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:18164265lifeskim:mentionsumls-concept:C1280464lld:lifeskim
pubmed-article:18164265pubmed:issue1-2lld:pubmed
pubmed-article:18164265pubmed:dateCreated2008-2-1lld:pubmed
pubmed-article:18164265pubmed:abstractTextPatients with Gaucher disease show signs of insulin resistance. The ganglioside GM3 has recently shown to be a negative regulator of insulin sensitivity. In fibroblasts of Gaucher patients, deficient in degradation of glucosylceramide, an increased anabolism of this lipid to gangliosides occurs. The goal of the current study was to establish whether GM3 is elevated in plasma of type I Gaucher disease patients, and is related to disease manifestations.lld:pubmed
pubmed-article:18164265pubmed:languageenglld:pubmed
pubmed-article:18164265pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18164265pubmed:citationSubsetIMlld:pubmed
pubmed-article:18164265pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18164265pubmed:statusMEDLINElld:pubmed
pubmed-article:18164265pubmed:monthMarlld:pubmed
pubmed-article:18164265pubmed:issn0009-8981lld:pubmed
pubmed-article:18164265pubmed:authorpubmed-author:GarcíaL DLDlld:pubmed
pubmed-article:18164265pubmed:authorpubmed-author:HollakCarla...lld:pubmed
pubmed-article:18164265pubmed:authorpubmed-author:KuiperSijmenSlld:pubmed
pubmed-article:18164265pubmed:authorpubmed-author:AertsJohannes...lld:pubmed
pubmed-article:18164265pubmed:authorpubmed-author:Ghauharali-va...lld:pubmed
pubmed-article:18164265pubmed:authorpubmed-author:LangeveldMirj...lld:pubmed
pubmed-article:18164265pubmed:authorpubmed-author:PoppemaAldiAlld:pubmed
pubmed-article:18164265pubmed:issnTypePrintlld:pubmed
pubmed-article:18164265pubmed:volume389lld:pubmed
pubmed-article:18164265pubmed:ownerNLMlld:pubmed
pubmed-article:18164265pubmed:authorsCompleteYlld:pubmed
pubmed-article:18164265pubmed:pagination109-13lld:pubmed
pubmed-article:18164265pubmed:meshHeadingpubmed-meshheading:18164265...lld:pubmed
pubmed-article:18164265pubmed:meshHeadingpubmed-meshheading:18164265...lld:pubmed
pubmed-article:18164265pubmed:meshHeadingpubmed-meshheading:18164265...lld:pubmed
pubmed-article:18164265pubmed:meshHeadingpubmed-meshheading:18164265...lld:pubmed
pubmed-article:18164265pubmed:meshHeadingpubmed-meshheading:18164265...lld:pubmed
pubmed-article:18164265pubmed:year2008lld:pubmed
pubmed-article:18164265pubmed:articleTitleProminent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease.lld:pubmed
pubmed-article:18164265pubmed:affiliationDepartment of Medical Biochemistry and Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands.lld:pubmed
pubmed-article:18164265pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18164265pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18164265lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18164265lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18164265lld:pubmed